Zealand Pharma slips on Lantus combination delay
This article was originally published in Scrip
Executive Summary
Zealand Pharma's share price has slipped by DKK3 a share (4%) to DKK67 a share in early trading on 28 July in response to news that partner Sanofi is to begin Phase III trials in early-2013 with a Lantus combination product – around 12 months later than expected. The share price movement wiped DKK68.6 million ($13.45 million) off the company's value.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.